Phase II clinical trial of AGN 209323 [EHT/AGN 0001] for the treatment of neuropathic pain.
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2011
At a glance
- Drugs AGN 209323 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2011 New trial record